Recursion Pharmaceuticals, Inc.
RXRXBiotechnology
$4.03−4.95%As of Oct 30vs prior close
- Market cap
- $2.4B
- P/E (TTM)
- –
- From 52W high
- −28.67%
- EPS (LTM)
- -$1.00
- Revenue (LTM)
- $54.9M
- Net margin
- -945.92%
- Dividend yield
- 0.00%
Nomior Score
19
Fragile PremiumSpeculativeBottom 6% of the scored universe
Growth57
Quality29
Value32
Momentum21
Resilience24
Growth
+78.37%revenue a year over 6 fiscal years
YE19 $2.3MLTM $54.9M
Connections
Revenue to profitQ2 YE26
The gross loss was 50% of revenue, wider by 45 pts on a year.
Who owns it
2funds